[Immune Reconstitution after BTKi Treatment in Chronic Lymphocytic Leukemia]

Area of Science:

• Hematology
• Immunology
• Oncology

Context:

• Chronic lymphocytic leukemia (CLL) is a B-cell malignancy characterized by the accumulation of malignant B lymphocytes.
• BTK inhibitors (BTKi) have emerged as a targeted therapy for CLL, offering a more precise approach than traditional chemotherapy.
• Understanding the impact of BTKi on immune reconstitution is crucial for managing long-term outcomes and potential complications in CLL patients.

Purpose:

• To investigate the effects of Bruton's tyrosine kinase inhibitor (BTKi) treatment on immune reconstitution in patients diagnosed with chronic lymphocytic leukemia (CLL).
• To analyze changes in B-cell and T-cell subpopulations, immunoglobulin levels, and cytokine profiles following BTKi therapy in CLL.

Summary:

• Retrospective analysis of 59 CLL patients treated with BTKi revealed significant reduction in malignant B-cell clones (CD5+/CD19+) within one year.
• BTKi treatment led to increased IgA levels, altered T-cell subpopulations (increased CD4+ and CD8+ cells), and modulated cytokine expression (upregulated IL-2, downregulated IL-4 and IFN-γ).
• Importantly, BTKi therapy promoted the recovery of T-cell receptor (TCR) and B-cell receptor (BCR) diversity, particularly in patients achieving complete remission.

Impact:

• BTKi treatment demonstrates a multifaceted role in immune reconstitution for CLL patients, extending beyond direct tumor cell reduction.
• The observed restoration of immune cell populations and diversity suggests a potential for improved long-term immune surveillance and reduced susceptibility to infections.
• These findings highlight BTKi as a valuable therapeutic strategy that not only targets CLL but also contributes to the recovery of the patient's overall immune function.